keyword
MENU ▼
Read by QxMD icon Read
search

Androgen deprivation therapy

keyword
https://www.readbyqxmd.com/read/28333019/a-comparison-between-low-dose-rate-brachytherapy-with-or-without-androgen-deprivation-external-beam-radiation-therapy-with-or-without-androgen-deprivation-and-radical-prostatectomy-with-or-without-adjuvant-or-salvage-radiation-therapy-for-high-risk-prostate
#1
Jay P Ciezki, Michael Weller, Chandana A Reddy, Jeffrey Kittel, Harguneet Singh, Rahul Tendulkar, Kevin L Stephans, James Ulchaker, Kenneth Angermeier, Andrew Stephenson, Steven Campbell, Georges-Pascal Haber, Eric A Klein
PURPOSE: We compare the efficacy and toxicity among the 3 major modalities available used to treat high-risk prostate cancer (HRCaP). METHODS AND MATERIALS: From 1996 to 2012, 2557 HRCaP patients were treated: 734 received external beam radiation therapy (EBRT) with or without androgen deprivation therapy (ADT), 515 received low-dose-rate prostate brachytherapy (LDR) with or without ADT, and 1308 received radical prostatectomy (RP) with or without EBRT. Biochemical relapse-free survival (bRFS), clinical relapse-free survival (cRFS), and prostate cancer-specific mortality (PCSM) were assessed...
April 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28333018/nationwide-multicenter-retrospective-study-on-high-dose-rate-brachytherapy-as-monotherapy-for-prostate-cancer
#2
Yasuo Yoshioka, Tadayuki Kotsuma, Akira Komiya, Shinji Kariya, Koji Konishi, Norio Nonomura, Kazuhiko Ogawa, Eiichi Tanaka, Kensaku Nishimura, Yasuyoshi Fujiuchi, Hiroshi Kitamura, Takuji Yamagami, Ichiro Yamasaki, Kazuo Nishimura, Teruki Teshima, Katsumasa Nakamura, Jun Itami
PURPOSE: To present, analyze, and discuss results of a nationwide, multicenter, retrospective study on high-dose-rate brachytherapy (HDR-BT) as monotherapy for low-, intermediate-, and high-risk prostate cancer. METHODS AND MATERIALS: From 1995 through 2013, 524 patients, 73 (14%) with low-risk, 207 (40%) with intermediate-risk, and 244 (47%) with high-risk prostate cancer, were treated with HDR-BT as monotherapy at 5 institutions in Japan. Dose fractionations were 27 Gy/2 fractions for 69 patients (13%), 45...
April 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28333017/effect-of-prostate-magnetic-resonance-imaging-ultrasound-fusion-guided-biopsy-on-radiation-treatment-recommendations
#3
Aaron Reed, Luca F Valle, Uma Shankavaram, Andra Krauze, Aradhana Kaushal, Erica Schott, Theresa Cooley-Zgela, Bradford Wood, Peter Pinto, Peter Choyke, Baris Turkbey, Deborah E Citrin
PURPOSE: Targeted magnetic resonance imaging (MRI)/ultrasound fusion prostate biopsy (MRI-Bx) has recently been compared with the standard of care extended sextant ultrasound-guided prostate biopsy (SOC-Bx), with the former associated with an increased rate of detection of clinically significant prostate cancer. The present study sought to determine the influence of MRI-Bx on radiation therapy and androgen deprivation therapy (ADT) recommendations. METHODS AND MATERIALS: All patients who had received radiation treatment and had undergone SOC-Bx and MRI-Bx at our institution were included...
April 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28325650/the-potential-role-of-follicle-stimulating-hormone-in-the-cardiovascular-metabolic-skeletal-and-cognitive-effects-associated-with-androgen-deprivation-therapy
#4
REVIEW
E David Crawford, Andrew V Schally, Jehonathan H Pinthus, Norman L Block, Ferenc G Rick, Marc B Garnick, Robert H Eckel, Thomas E Keane, Neal D Shore, David N Dahdal, Thomas J R Beveridge, Dennis C Marshall
PURPOSE: To explore how follicle-stimulating hormone (FSH) may contribute to cardiovascular, metabolic, skeletal, and cognitive events in men treated for prostate cancer, with various forms of androgen deprivation therapy (ADT). MATERIALS AND METHODS: A colloquium of prostate cancer experts was convened in May 2015, to discuss the role of FSH in the development of unwanted effects associated with ADT. Subsequently, a literature review (Medline, PubMed, and relevant congress abstract databases) was performed to further explore and evaluate the collected evidence...
March 18, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28325637/long-term-control-of-oligometastatic-prostate-cancer-after-stereotactic-body-radiotherapy-in-the-absence-of-androgen-deprivation-therapy-a%C3%A2-case-report
#5
Mark C Markowski, Philip Imus, Jean L Wright, Douglas Schottenstein, Channing J Paller
No abstract text is available yet for this article.
February 27, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28323339/adjuvant-radiation-therapy-androgen-deprivation-and-docetaxel-for-high-risk-prostate-cancer-postprostatectomy-results-of-nrg-oncology-rtog-study-0621
#6
Mark D Hurwitz, Jonathan Harris, Oliver Sartor, Ying Xiao, Bobby Shayegan, Paul W Sperduto, Kasra R Badiozamani, Colleen A F Lawton, Eric M Horwitz, Jeff M Michalski, Kevin Roof, David C Beyer, Qiang Zhang, Howard M Sandler
BACKGROUND: Phase 3 trials have demonstrated a benefit from adjuvant radiation therapy (ART) for men who have adverse factors at radical prostatectomy (RP). However, some patients have a high risk of progression despite ART. The role of systemic therapy with ART in this high-risk group remains to be defined. METHODS: Patients who had either a post-RP prostate-specific antigen (PSA) nadir > 0.2 ng/mL and a Gleason score ≥7 or a PSA nadir ≤0.2 ng/mL, a Gleason score ≥8, and a pathologic tumor (pT) classification ≥ pT3 received 6 months of androgen-deprivation therapy (ADT) plus radiotherapy and 6 cycles of docetaxel...
March 21, 2017: Cancer
https://www.readbyqxmd.com/read/28323036/targeting-androgen-receptor-versus-targeting-androgens-to-suppress-castration-resistant-prostate-cancer
#7
Changcheng Guo, Shuyuan Yeh, Yuanjie Niu, Gonghui Li, Junhua Zheng, Lei Li, Chawnshang Chang
Prostate cancer (PCa) is the 2nd leading cause of cancer-related death among men in the United States and its progression is tightly associated with the androgen/androgen receptor (AR) signals. Men castrated before puberty (eunuchs) or men with inherited deficiency of type II 5α-reductase (with failure to convert testosterone to the more potent dihydrotestosterone) (DHT) do not develop PCa. To date, androgen deprivation therapy (ADT) with anti-androgen treatments to reduce or prevent androgens from binding to the AR remains the main therapeutic option for advanced PCa since its discovery by Huggins and Hodges in 1941...
March 18, 2017: Cancer Letters
https://www.readbyqxmd.com/read/28321773/salivary-duct-carcinoma-an-update-on-morphologic-mimics-and-diagnostic-use-of-androgen-receptor-immunohistochemistry
#8
Aaron M Udager, Simion I Chiosea
More than 15 years ago, seminal studies by Dr. E. Leon Barnes and colleagues transformed our understanding of salivary duct carcinoma (SDC) and, in doing so, paved the way for contemporary diagnostic and therapeutic approaches to this aggressive salivary adenocarcinoma. In particular, attention to the apocrine phenotype of SDC and expression of androgen receptor (AR) by immunohistochemistry has improved the diagnostic accuracy and showed how SDC can be reliably distinguished from its morphologic mimics (i.e...
March 20, 2017: Head and Neck Pathology
https://www.readbyqxmd.com/read/28321130/effective-combinatorial-immunotherapy-for-castration-resistant-prostate-cancer
#9
Xin Lu, James W Horner, Erin Paul, Xiaoying Shang, Patricia Troncoso, Pingna Deng, Shan Jiang, Qing Chang, Denise J Spring, Padmanee Sharma, John A Zebala, Dean Y Maeda, Y Alan Wang, Ronald A DePinho
A significant fraction of patients with advanced prostate cancer treated with androgen deprivation therapy experience relapse with relentless progression to lethal metastatic castration-resistant prostate cancer (mCRPC). Immune checkpoint blockade using antibodies against cytotoxic-T-lymphocyte-associated protein 4 (CTLA4) or programmed cell death 1/programmed cell death 1 ligand 1 (PD1/PD-L1) generates durable therapeutic responses in a significant subset of patients across a variety of cancer types. However, mCRPC showed overwhelming de novo resistance to immune checkpoint blockade, motivating a search for targeted therapies that overcome this resistance...
March 20, 2017: Nature
https://www.readbyqxmd.com/read/28319807/targeting-nf-kappa-b-signaling-by-artesunate-restores-sensitivity-of-castrate-resistant-prostate-cancer-cells-to-antiandrogens
#10
Jessica J Nunes, Swaroop K Pandey, Anjali Yadav, Sakshi Goel, Bushra Ateeq
Androgen deprivation therapy (ADT) is the most preferred treatment for men with metastatic prostate cancer (PCa). However, the disease eventually progresses and develops resistance to ADT in majority of the patients, leading to the emergence of metastatic castration-resistant prostate cancer (mCRPC). Here, we assessed artesunate (AS), an artemisinin derivative, for its anticancer properties and ability to alleviate resistance to androgen receptor (AR) antagonists. We have shown AS in combination with bicalutamide (Bic) attenuates the oncogenic properties of the castrate-resistant (PC3, 22RV1) and androgen-responsive (LNCaP) PCa cells...
March 16, 2017: Neoplasia: An International Journal for Oncology Research
https://www.readbyqxmd.com/read/28319589/exercise-improves-v-combining-dot-above-o-2max-and-body-composition-in-adt-treated-prostate-cancer-patients
#11
Bradley A Wall, Daniel A Galvão, Naeem Fatehee, Dennis R Taaffe, Nigel Spry, David Joseph, Jeffrey J Hebert, Robert U Newton
INTRODUCTION: Prostate cancer is the most common cancer in men and patients treated with androgen deprivation therapy (ADT) experience unfavourbale changes in body composition and associated metabolic complications, which can increase the risk of cardiovascular disease. We examined the effect of a 6-month program of aerobic and resistance exercise aimed at improving body composition and cardiorespiratory health in this population. METHODS: Ninety-seven men (43-90 years) with localized prostate cancer receiving ADT were randomized to either exercise (EX, n=50) or usual care (CON, n=47)...
March 18, 2017: Medicine and Science in Sports and Exercise
https://www.readbyqxmd.com/read/28319496/the-utility-of-68ga-psma-pet-ct-in-poorly-differentiated-metastatic-prostate-cancer
#12
Mehmet Onur Demirkol, Murat Can Kiremit, Omer Acar, Burcu Ucar, Yesim Saglican
We aimed to emphasize how useful PSMA PET/CT findings can be while trying to restage prostate cancer after radical prostatectomy in the presence of low prostate-specific antigen values. A 64-year-old man with pT3b N1 M0 Gleason 7 adenocarcinoma of the prostate presented 5 years postoperatively with a palpable axillary mass, whereas his prostate-specific antigen was 0.08 ng/mL. Conventional imaging studies and histopathologic findings of the axillary mass biopsy revealed inconclusive results. Ga-PSMA PET/CT demonstrated PSMA-positive metastatic lesions, the largest one being located in the right axilla...
March 17, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28301348/discord-among-radiation-oncologists-and-urologists-in-the-postoperative-management-of-high-risk-prostate-cancer
#13
Amar U Kishan, Gillian Duchesne, Pin-Chieh Wang, Jean-Claude M Rwigema, Arun U Kishan, Christopher Saigal, Matthew Rettig, Michael L Steinberg, Christopher R King
OBJECTIVE: To query specialty-specific differences regarding postoperative radiotherapy (RT) for high-risk prostate cancer. MATERIALS AND METHODS: Electronic mail survey of radiation oncologists (ROs) and urologists. We sought to maximize absolute response number to capture contemporary practice ethos. The outcome of interest was association between response and specialty. Training level/expertise, practice setting, percentage of consultation caseload consisting of high-risk prostate cancer, and nationality were set as effect modifiers for multivariate logistic regression...
March 15, 2017: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28296582/randomized-trial-of-a-hypofractionated-radiation-regimen-for-the-treatment-of-localized-prostate-cancer
#14
Charles N Catton, Himu Lukka, Chu-Shu Gu, Jarad M Martin, Stéphane Supiot, Peter W M Chung, Glenn S Bauman, Jean-Paul Bahary, Shahida Ahmed, Patrick Cheung, Keen Hun Tai, Jackson S Wu, Matthew B Parliament, Theodoros Tsakiridis, Tom B Corbett, Colin Tang, Ian S Dayes, Padraig Warde, Tim K Craig, Jim A Julian, Mark N Levine
Purpose Men with localized prostate cancer often are treated with external radiotherapy (RT) over 8 to 9 weeks. Hypofractionated RT is given over a shorter time with larger doses per treatment than standard RT. We hypothesized that hypofractionation versus conventional fractionation is similar in efficacy without increased toxicity. Patients and Methods We conducted a multicenter randomized noninferiority trial in intermediate-risk prostate cancer (T1 to 2a, Gleason score ≤ 6, and prostate-specific antigen [PSA] 10...
March 15, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28295408/circulating-tumor-cells-as-a-marker-for-progression-free-survival-in-metastatic-castration-na%C3%A3-ve-prostate-cancer
#15
Andreas Josefsson, Anna Linder, Despina Flondell Site, Giacomo Canesin, Anna Stiehm, Aseem Anand, Anders Bjartell, Jan-Erik Damber, Karin Welén
BACKGROUND: Analysis of circulating tumor cells (CTC) is a promising prognostic marker in castration-resistant prostate cancer (CRPC). The aim of this study was to investigate CTC detection and phenotyping as prognostic biomarkers for response to primary androgen deprivation therapy (ADT) of metastatic prostate cancer (PC). METHODS: PC patients presenting with a prostate specific antigen (PSA) >80 ng/ml and/or metastatic disease, intended for ADT were enrolled in the study...
March 10, 2017: Prostate
https://www.readbyqxmd.com/read/28294068/cognitive-impacts-of-estrogen-treatment-in-androgen-deprived-males-what-needs-to-be-resolved
#16
Erik Wibowo
BACKGROUND: Many prostate cancer (PCa) patients are on androgen deprivation therapy (ADT) as part of their cancer treatments but ADT may cause cognitive impairments. ADT depletes men of both androgen and estrogen. Whether estradiol supplementation can improve cognitive impairments in patients on ADT is understudied. OBJECTIVE: To summarize data on the effects of estradiol treatment on cognitive function of androgen-deprived genetic male populations (PCa patients and male-to-female transsexuals) and castrated male animals...
March 13, 2017: Current Neuropharmacology
https://www.readbyqxmd.com/read/28282307/health-related-quality-of-life-after-the-diagnosis-of-locally-advanced-or-advanced-prostate-cancer-a-longitudinal-study
#17
Leah Zajdlewicz, Melissa K Hyde, Stephen J Lepore, Robert A Gardiner, Suzanne K Chambers
BACKGROUND: Approximately 20% of men with a diagnosis of prostate cancer present with locally advanced or advanced disease. Few studies consider longer-term impact of disease progression and treatment adverse effects on health-related quality of life (QoL) of these men. OBJECTIVE: Describe changes in health-related QoL over 5 years for men with newly diagnosed locally advanced or advanced prostate cancer. INTERVENTIONS/METHODS: Eighty-one men with locally advanced or advanced prostate cancer referred to the study by their treating urologist completed a self-administered questionnaire assessing distress, cancer-specific distress, decision regret, satisfaction with life, and global and disease-specific health-related QoL...
March 10, 2017: Cancer Nursing
https://www.readbyqxmd.com/read/28279064/cancer-specific-mortality-among-korean-men-with-localized-or-locally-advanced-prostate-cancer-treated-with-radical-prostatectomy-versus-radiotherapy-a-multi-center-study-using-propensity-scoring-and-competing-risk-regression-analyses
#18
Kyo Chul Koo, Jin Seon Cho, Woo Jin Bang, Seung Hwan Lee, Sung Yong Cho, Sun Il Kim, Se Joong Kim, Koon Ho Rha, Sung Joon Hong, Byung Ha Chung
Purpose: Studies comparing radical prostatectomy (RP) outcomes with those of radiotherapy with or without androgen deprivation therapy (RT±ADT) for prostate cancer (PCa) have yielded conflicting results. Therefore, we used propensity score-matched analysis and competing risk regression analysis to compare cancer-specific mortality (CSM) and other-cause mortality (OCM) between these two treatments. Materials and Methods: The multi-center, Severance Urological Oncology Group registry was utilized to identify 3,028 patients with clinically localized or locally advanced PCa treated by RP (n=2,521) or RT±ADT (n=507) between 2000 and 2016...
March 8, 2017: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://www.readbyqxmd.com/read/28275218/epigenomic-regulation-of-androgen-receptor-signaling-potential-role-in-prostate-cancer-therapy
#19
REVIEW
Vito Cucchiara, Joy C Yang, Vincenzo Mirone, Allen C Gao, Michael G Rosenfeld, Christopher P Evans
Androgen receptor (AR) signaling remains the major oncogenic pathway in prostate cancer (PCa). Androgen-deprivation therapy (ADT) is the principle treatment for locally advanced and metastatic disease. However, a significant number of patients acquire treatment resistance leading to castration resistant prostate cancer (CRPC). Epigenetics, the study of heritable and reversible changes in gene expression without alterations in DNA sequences, is a crucial regulatory step in AR signaling. We and others, recently described the technological advance Chem-seq, a method to identify the interaction between a drug and the genome...
January 16, 2017: Cancers
https://www.readbyqxmd.com/read/28274403/long-term-results-of-adjuvant-versus-early-salvage-postprostatectomy-radiation-a-large-single-institutional-experience
#20
Daniela L Buscariollo, Michael Drumm, Andrzej Niemierko, Rebecca H Clayman, Sigolene Galland-Girodet, Danielle Rodin, Adam S Feldman, Douglas M Dahl, Francis J McGovern, Aria F Olumi, Alec Eidelman, William U Shipley, Anthony L Zietman, Jason A Efstathiou
PURPOSE: The purpose of this study was to evaluate freedom from biochemical failure (FFBF), freedom from androgen deprivation therapy (FFADT), freedom from distant metastases (FFDM), and overall survival (OS) after adjuvant radiation therapy (ART) versus early salvage radiation therapy (ESRT) in men with prostate cancer and adverse pathologic features (pT3 and/or positive surgical margins). METHODS AND MATERIALS: Of 718 patients consecutively treated with postoperative radiation therapy (RT) for prostate cancer between 1992 and 2013, we retrospectively identified 171 men receiving ART and 230 receiving ESRT (RT delivered at a prostate-specific antigen level ≤0...
March 2017: Practical Radiation Oncology
keyword
keyword
58120
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"